Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01955161 · ClinicalTrials.gov registry record · Phase 3

Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil

A Phase 3 study of Alzheimers Disease, sponsored by H. Lundbeck A/S.

Completed
Registry status
Phase 3
Development phase
933
Enrollment target
20
Study locations

NCT01955161 is a Phase 3 study of Alzheimers Disease that has completed, run by H. Lundbeck A/S. The registered enrollment target is 933 participants, below the 4,055-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01955161, a Phase 3 study of Alzheimers Disease, has completed, sponsored by H. Lundbeck A/S.

COMPLETED
Registry status
Phase 3
Development phase
933 participants
Enrollment target
20
Study locations

Study Summary

To establish efficacy of idalopirdine as adjunctive therapy to donepezil for symptomatic treatment of patients with mild-to-moderate Alzheimer's disease (AD).

Conditions Studied

Alzheimers Disease

Interventions

  • DRUG Placebo
  • DRUG Idalopirdine

Study Locations (20)

California

  • US053 - Glendale
  • US023 - Imperial
  • US015 - La Jolla
  • US045 - Long Beach
  • US002 - Los Angeles
  • US058 - San Francisco
  • US018 - Santa Ana

Florida

  • US042 - Boca Raton
  • US021 - Bradenton
  • US050 - Brooksville
  • US019 - Orlando
  • US038 - Port Charlotte
  • US001 - West Palm Beach

Alabama

  • US027 - Birmingham

Arizona

  • US012 - Phoenix

Arkansas

  • US024 - Little Rock

Colorado

  • US060 - Denver

Georgia

  • US020 - Atlanta

Hawaii

  • US048 - Kailua

Trial Details

FieldValue
Enrollment Target 933 participants
Start Date 2013-10
Est. Completion 2016-07
Phase Phase 3

Sponsor

H. Lundbeck A/S

72 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01955161

The ClinicalTrials.gov registry entry for NCT01955161 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 933 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,055-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (77% lower). The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01955161 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Alabama.

Frequently Asked Questions

What is clinical trial NCT01955161 about?

NCT01955161 is a clinical study titled "Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil". To establish efficacy of idalopirdine as adjunctive therapy to donepezil for symptomatic treatment of patients with mild-to-moderate Alzheimer's disease (AD).

What is the current status of trial NCT01955161?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 933 participants. The study started on 2013-10. Estimated completion is 2016-07.

What conditions does trial NCT01955161 study?

This clinical trial studies the following conditions: Alzheimers Disease.

What interventions are being tested in trial NCT01955161?

The interventions under investigation include: Placebo (DRUG), Idalopirdine (DRUG).

Who is sponsoring clinical trial NCT01955161?

This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01955161 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimers Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alzheimers Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.